Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723198 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Phase 3 study of Skin Diseases and Alopecia, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
- 20
- Study locations
NCT05723198: Recruiting Phase 3 study of Skin Diseases and Alopecia, sponsored by Eli Lilly and Company.
NCT05723198 is a Phase 3 study of Skin Diseases and Alopecia that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 595 participants, above the 167-participant average among 14 other Skin Diseases trials with a reported enrollment target (256% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05723198, a Phase 3 study of Skin Diseases and Alopecia, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baricitinib
Study Locations (20)
Florida
- Skin Care Research, Inc - Boca Raton
- Florida Academic Centers Research and Education, LLC - Coral Gables
- D&H Doral Research Center LLC - Doral
- Skin Care Research, Inc - Hollywood
- Solutions Through Advanced Research, Inc. - Jacksonville
- University of Miami Miller School of Medicine - Miami
- Pediatric Skin Research, LLC - Miami
California
- California Dermatology & Clinical Research Institute - Encinitas
- Dermatology Research Associates - Los Angeles
- University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology - San Diego
- The Permanente Medical Group, Inc. - San Francisco
- Southern California Dermatology, Inc. - Santa Ana
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
- University of Alabama at Birmingham - Birmingham
Illinois
- Northwestern University - Chicago
- Northshore University Healthsystem - Skokie
Arizona
- Investigate MD - Scottsdale
Connecticut
- Dermatology Physicians of Connecticut - Fairfield
Georgia
- Skin Care Physicians of Georgia - Macon
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2029-08 |
| Phase | Phase 3 |
What NCT05723198 shows while recruiting
NCT05723198 is an interventional study that assigns participants to a tested intervention. The registered 595 participants enrollment target is mid-sized for trials with a published cap, above the 167-participant average among 14 other Skin Diseases trials with a reported enrollment target (256% higher).
The record links to 6 conditions, with Skin Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05723198 names 20 study sites across 8 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05723198 about?
NCT05723198 is a clinical study titled "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata". The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind ...
What is the current status of trial NCT05723198?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2023-02-27. Estimated completion is 2029-08.
What conditions does trial NCT05723198 study?
This clinical trial studies the following conditions: Skin Diseases, Alopecia, Pathological Conditions, Anatomical, Hypotrichosis, Hair Diseases.
What interventions are being tested in trial NCT05723198?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT05723198?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05723198 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05723198's enrollment target sits among peer trials
595 2nd of 14 the highest of 14 other Skin Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
OCT Vibrography for Biomechanical Properties of Tissues
RECRUITING · NA
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
RECRUITING · Early Phase 1
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
-
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI